Health News Releases

  • Today December 20
August 14, 2019 11:45
Terns Pharmaceuticals Announces Positive Interim Results From Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced the
August 13, 2019 09:48
Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types
August 12, 2019 11:43
Mary Kay Reveals Research on Skin Barrier Function and Facial Redness at the Chinese Association of Integrative Medicine Meeting
As one of the world’s leading skincare innovators in the direct selling and cosmetic industries, Mary Kay continued its decades-long commitment to skin science research by revealing the results of a s
August 08, 2019 09:59
Study Demonstrates Reduction in Mortality Using Masimo Noninvasive, Continuous Hemoglobin (SpHb®) and Pleth Variability Index (PVi®) Monitoring
Masimo (NASDAQ: MASI) announced today that in a study published in the Journal of Clinical Monitoring and Computing, researchers investigated the effects of implementing a hospital-wide fluid and bloo
August 06, 2019 10:59
SpeeDx Pty. Ltd. Raises $15 Million From U.S. Investment Partnership
SpeeDx Pty. Ltd., the developer of transformative new molecular diagnostic solutions, today announced it had raised up to US $10 million in additional equity investment from US-based Northpond Venture
August 06, 2019 10:18
Masimo Announces CE Marking of Neonatal Indication for Noninvasive, Continuous Hemoglobin Monitoring (SpHb®)
Masimo (NASDAQ: MASI) announced today the CE marking of SpHb®, noninvasive and continuous hemoglobin monitoring, for neonatal and infant patients (< 3 kg). With this clearance, the benefits of SpHb ar
August 05, 2019 09:29
Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Boehringer Ingelheim today announced updated, interim analysis results from the GioTag study, showing that initiating treatment with afatinib followed by osimertinib provided an overall survival (OS)
August 02, 2019 18:58
Alvogen and Lotus Announce First to Launch Generic Version of Navelbine® Softgel Capsule in Europe
Alvogen today announced that its subsidiary Lotus Pharmaceuticals has launched Vinorelbine 20, 30 and 80mg soft capsules in Europe. The product is the generic version of Pierre Fabre Médicament’s Nave
August 02, 2019 18:15
Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful Integration
Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO: 4502/NYSE: TAK) today announces that the Takeda Board of Directors has approved key performance indicators (KPIs) to be included in both the co
August 02, 2019 17:16
Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year
Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): Underlying Revenue declined -0.8% vs FY2018 Q1 pro-forma revenue[1] · Takeda’s 14 global brands, with an aggregate revenue of 270.2
August 01, 2019 18:59
Biological E and GVK BIO Announce Strategic R&D Partnership
GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and BE Pharmaceuticals Inc (BE Inc), a rapidly growing pharmaceutical company that develops, manufactures and markets c
July 31, 2019 17:33
Renowned Nutrigenomics Authority Affirms the Exceptional Immunobiotic Benefits of House Wellness Foods’ Key Ingredient, HK L-137
Lactobacillus HK L-137, the primary constituent of House Wellness Foods Immuno-LP20, has received one of its strongest endorsements to date from nutritional biochemist Dr. Christine Houghton, Ph.D.,BS
July 30, 2019 22:05
The Healthcare+ Expo Taiwan Continues to Lead a Medical Innovation Hub With Its Strength in Digital Health, Health Tech and Medicine
Following the success last year, the Healthcare+ Expo sees a rapid growth in size and significance of procurement, networking and marketing. The Expo is now regarded as a primary event in Asia, attrac
July 30, 2019 11:07
NEC Acquires Norwegian Bioinformatics Company, OncoImmunity AS
NEC Corporation (NEC; TOKYO: 6701) today announced the acquisition of OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight ag
July 29, 2019 16:00
Philanthropist Tej Kohli Pledges $2 Million Gift to Champion Biotech Solutions for Eliminating Corneal Blindness Worldwide By 2030
Tej Kohli, a London-based billionaire who made his fortune during the dotcom boom selling e-commerce payments software, has pledged $2 million to Massachusetts Eye and Ear in Boston to fund innovation
July 25, 2019 14:16
Multi-Lactobacillus BARU Developed by GSL-BIO Showed Excellent Effects on Environmental Improvement
BARU, the multi-lactobacillus developed by a Korean microorganism company GSL-BIO, has been proven to improve water quality drastically. BARU is a multi-lactobacillus made of seed microorganism tha
July 23, 2019 16:09
Study Investigates the Ability of Continuous Noninvasive Hemoglobin Monitoring with Masimo SpHb® to Reflect Acute Hemodilution During Incremental Fluid Administration
Masimo (NASDAQ: MASI) announced today that in a study recently published in Anesthesia & Analgesia, researchers evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo Sp
July 22, 2019 14:43
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with or
July 22, 2019 14:35
Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcuta
July 19, 2019 15:22
Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics
Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxi
July 17, 2019 13:13
St. Luke’s Medical Center Selects Allscripts Sunrise™
St. Luke’s Medical Center, located in the Philippines, has selected Allscripts (NASDAQ: MDRX) Sunrise™ Acute Care as its electronic health record (EHR) to achieve the goal of standardization across it
July 16, 2019 14:20
Gemtech Targets the Asian Market with Its Medical Devices and Coating and Plating, and Special Spray Products
Gemtech Co., Ltd. is enhancing its R&D and marketing capability to expand the business into the Asian market with its medical devices, coating and plating facility, and special spray products. Gemt
July 16, 2019 14:15
SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test
SpeeDx Pty. Ltd. today announced ResistancePlus® MG has been cleared by Health Canada and is now available for sale across all Canadian provinces (not currently available in the U.S.). The molecular d
July 16, 2019 14:08
ResMed Inc. Completes $500M Private Placement Debt Offering
ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000
July 16, 2019 13:03
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeut
25 per page50 per page75 per page100 per page